false000177078700017707872024-08-062024-08-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2024

Logo-10x.jpg
10x Genomics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-39035
45-5614458
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
6230 Stoneridge Mall Road
Pleasanton, California 94588
(925) 401-7300
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
___________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol
Name of each exchange
on which registered
Class A common stock, par value $0.00001 per share
TXG
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐


Item 2.02 Results of Operations and Financial Condition.
On August 8, 2024, 10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1.
The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 8, 2024, the Company announced that Adam S. Taich will be joining the Company as its Chief Financial Officer, effective August 12, 2024, replacing Justin J. McAnear, who on August 6, 2024 notified the Company of his intention to resign and who will continue to provide transition services as an employee of the Company through August 30, 2024. Effective as of August 12, 2024, Mr. Taich will serve as the Company’s Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer.
Mr. Taich, 49, previously served as Chief Strategy Officer of Standard BioTools Inc. from January 2024 to July 2024. He previously served as interim Chief Executive Officer of SomaLogic, Inc., a proteomics company, from March 2023 until SomaLogic’s acquisition by Standard BioTools in January 2024. Mr. Taich served as SomaLogic’s Chief Business Officer from November 2021 to March 2023 as well as SomaLogic’s Executive Vice President of Life Sciences from April 2022 to March 2023. Prior to joining SomaLogic, Mr. Taich spent 19 years at ThermoFisher Scientific, a global supplier of scientific instrumentation, reagents and software services, in various roles including as Vice President & General Manager—Molecular Biology from February 2020 to June 2021, Vice President—Strategy and Business Development from April 2018 to February 2020, Vice President & General Manager—Protein and Cell Analysis from October 2016 to April 2018, Vice President & General Manager—Global Services and Support from November 2013 to October 2016 and in various other roles from 2004 to 2013. Mr. Taich holds a B.A. in Political Science and Russian from Miami University in Oxford, Ohio.

In connection with his employment, Mr. Taich signed an offer letter with the Company on August 7, 2024 (the “Offer Letter”), which provides that Mr. Taich will receive an annual base salary of $500,000 and a target annual bonus equal to 60% of his eligible base salary. The Offer Letter also provides that, subject to approval by the Company’s Board of Directors, Mr. Taich will receive a grant of restricted stock units under the Company’s 2019 Omnibus Incentive Plan having a target value equal to $4,500,000 which will vest as to one fourth of such grant on August 21, 2025 and thereafter in equal quarterly installments for the following three years, subject to his continued service through each vesting date. Additionally, Mr. Taich shall also be eligible to participate in employee benefit plans and programs that are generally available to other senior executives of the Company located in the United States, including the Company’s Change in Control Severance Policy (the “Severance Policy”) discussed in the Company’s definitive proxy statement on Schedule 14A for its 2024 annual meeting of stockholders filed with the Securities and Exchange Commission (“SEC”) on April 26, 2024. Mr. Taich would be entitled to a lump sum severance payment equal to six (6) months of his base salary in effect at the time of his termination, subject to his execution and non-revocation of a release of claims, if he was terminated by us without Cause (as defined in the Severance Policy) prior to August 21, 2025.

Mr. Taich, in connection with his employment, has entered into the Company’s standard indemnification agreement, the form of which has been filed as Exhibit 10.17 to the Company’s Amendment No. 1 to Registration Statement on Form S-1 filed with the SEC on September 3, 2019 and the Company’s standard At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement which has been filed as Exhibit 10.16 to the Company’s Registration Statement on Form S-1 filed with the SEC on August 19, 2019.

There are no arrangements or understandings with any other person pursuant to which Mr. Taich was appointed as the Company’s Chief Financial Officer and there are no family relationships between Mr. Taich and any director or executive officer of the Company. Additionally, there are no transactions between Mr. Taich and the Company that would be required to be reported under Item 404(a) of Regulation S-K.
Item 8.01 Other Events.
On August 8, 2024, the Company issued a press release announcing Mr. Taich’s hiring and McAnear’s resignation, among other matters. A copy of such press release is attached hereto as Exhibit 99.2.


The information set forth in this Item 8.01 and in the press release attached Exhibit 99.2 is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No.
Description of Exhibits
99.1
99.2
104Cover Page Interactive Data File (embedded within the Inline XBRL document).


Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
10x Genomics, Inc.
By:
/s/ Eric S. Whitaker
Name:
Eric S. Whitaker
Title:
Chief Legal Officer
Date: August 8, 2024


Exhibit 99.1
a10x_logoxhorizontalxfullcb.jpg
10x Genomics Reports Second Quarter 2024 Financial Results
PLEASANTON, Calif. August 8, 2024 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024.
Recent Highlights
•Revenue was $153.1 million for the second quarter, a 4% increase over the corresponding period of 2023, primarily driven by stronger contributions from consumables.
•Began shipping Xenium Prime 5K, which measures 5,000 genes and features an enhanced chemistry to deliver excellent per-gene sensitivity, improved specificity and spatial fidelity, and integrated multimodal cell segmentation.
•Announced that the Garvan Institute of Medical Research selected Chromium GEM-X for its new TenK10K project, which intends to map 50 million human cells to identify unique genomic fingerprints of autoimmune diseases, heart diseases and cancer.
“While it’s a challenging macro environment, we saw strong demand for spatial and single cell consumables this quarter, fueled by significant product launches earlier this year,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “We remain confident in the strength, differentiation and long-term potential of our platforms as we evolve our commercial organization and continue to execute our strategy.”
Second Quarter 2024 Financial Results
Revenue was $153.1 million for the second quarter of 2024, a 4% increase from $146.8 million for the corresponding prior year period.
Gross margin was flat year over year at 68%.
Operating expenses were $146.0 million for the second quarter of 2024, a 10% decrease from $163.0 million for the corresponding prior year period. This decrease was primarily driven by lower personnel expenses, including stock-based compensation expense, and a decrease in laboratory materials and supplies.
Operating loss was $41.7 million for the second quarter of 2024, as compared to $63.4 million for the corresponding prior year period. Operating loss includes $38.5 million of stock-based compensation for the second quarter of 2024, as compared to $45.7 million of stock-based compensation for the corresponding prior year period.
Net loss was $37.9 million for the second quarter of 2024, as compared to a net loss of $62.4 million for the corresponding prior year period.
Cash and cash equivalents and marketable securities were $380.1 million as of June 30, 2024.
2024 Financial Guidance
10x Genomics is updating its outlook for the full year 2024. The company now expects revenue to be in the range of $640 million to $660 million versus a prior range of $670 million to $690 million. The updated range represents 3% to 7% growth over full year 2023 revenue.
Webcast and Conference Call Information
10x Genomics will host a conference call to discuss the second quarter 2024 financial results, business developments and outlook after market close on Thursday, August 8 , 2024 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the
1
a10x_logoxhorizontalxfullcb.jpg
conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s product momentum, potential, organization, strategy, demand, progress and launches, our expected performance advantages and benefits of using our products and services, customer usage and adoption of our products and our financial performance and results of operations, including our expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2023 and the company’s 10-Q for the quarter ended March 31, 2024 to be filed with the Securities and Exchange Commission (SEC) and elsewhere in the documents 10x Genomics, Inc. files with the SEC from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.


Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
2
a10x_logoxhorizontalxfullcb.jpg
10x Genomics, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
Three Months Ended
June 30,		Six Months Ended
June 30,
2024202320242023
Revenue (1)
$153,104 $146,819 $294,110 $281,104 
Cost of revenue (2)
48,884 47,207 96,976 83,102 
Gross profit104,220 99,612 197,134 198,002 
Operating expenses:
Research and development (2)
62,918 71,460 131,556 138,558 
Selling, general and administrative (2)
83,039 91,510 168,813 174,790 
Total operating expenses145,957 162,970 300,369 313,348 
Loss from operations(41,737)(63,358)(103,235)(115,346)
Other income (expense):
Interest income4,715 4,100 9,451 7,969 
Interest expense(1)(5)(2)(24)
Other expense, net(56)(1,504)(1,096)(3,020)
Total other income4,658 2,591 8,353 4,925 
Loss before provision for income taxes(37,079)(60,767)(94,882)(110,421)
Provision for income taxes818 1,647 2,964 2,740 
Net loss$(37,897)$(62,414)$(97,846)$(113,161)
Net loss per share, basic and diluted$(0.32)$(0.53)$(0.82)$(0.97)
Weighted-average shares of common stock used in computing net loss per share, basic and diluted120,066,972 116,707,672 119,461,485 116,166,776 

3
a10x_logoxhorizontalxfullcb.jpg
(1)The following table represents revenue by source for the periods indicated (in thousands). Spatial products includes the Company’s Visium and Xenium products:
Three Months Ended
June 30,		Six Months Ended
June 30,
2024202320242023
Instruments
Chromium$8,792 $12,859 $16,642 $24,485 
Spatial15,060 18,096 32,663 25,646 
Total instruments revenue23,852 30,955 49,305 50,131 
Consumables
Chromium94,108 100,794 178,035 201,890 
Spatial29,254 11,694 55,662 22,976 
Total consumables revenue123,362 112,488 233,697 224,866 
Services5,890 3,376 11,108 6,107 
Total revenue$153,104 $146,819 $294,110 $281,104 
The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2024202320242023
Americas
United States$89,672 $88,394 $165,309 $164,675 
Americas (excluding United States)3,419 3,149 7,412 5,664 
Total Americas93,091 91,543 172,721 170,339 
Europe, Middle East and Africa37,362 31,246 72,083 59,668 
Asia-Pacific
China13,738 12,755 27,662 26,786 
Asia-Pacific (excluding China)8,913 11,275 21,644 24,311 
Total Asia-Pacific22,651 24,030 49,306 51,097 
Total Revenue$153,104 $146,819 $294,110 $281,104 
(2)Includes stock-based compensation expense as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
(in thousands)
2024202320242023
Cost of revenue$2,247 $1,835 $4,280 $3,296 
Research and development17,862 19,560 34,750 37,340 
Selling, general and administrative18,383 24,301 35,591 47,161 
Total stock-based compensation expense$38,492 $45,696 $74,621 $87,797 
4
a10x_logoxhorizontalxfullcb.jpg
10x Genomics, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)
June 30,
2024		December 31,
2023
Assets
Current assets:
Cash and cash equivalents$379,824 $359,284 
Marketable securities269 29,411 
Accounts receivable, net91,178 114,832 
Inventory88,272 73,706 
Prepaid expenses and other current assets19,612 18,789 
Total current assets579,155 596,022 
Property and equipment, net263,285 279,571 
Operating lease right-of-use assets60,872 65,361 
Goodwill4,511 4,511 
Intangible assets, net16,658 16,616 
Other noncurrent assets5,187 3,062 
Total assets$929,668 $965,143 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$21,248 $15,738 
Accrued compensation and related benefits20,078 30,105 
Accrued expenses and other current liabilities42,437 56,648 
Deferred revenue16,436 13,150 
Operating lease liabilities10,820 11,521 
Total current liabilities111,019 127,162 
Operating lease liabilities, noncurrent78,662 83,849 
Deferred revenue, noncurrent11,358 8,814 
Other noncurrent liabilities4,571 4,275 
Total liabilities205,610 224,100 
Commitments and contingencies
Stockholders’ equity:
Preferred stock— — 
Common stock2 2 
Additional paid-in capital2,106,752 2,025,890 
Accumulated deficit(1,382,266)(1,284,420)
Accumulated other comprehensive loss(430)(429)
Total stockholders’ equity724,058 741,043 
Total liabilities and stockholders’ equity$929,668 $965,143 
5

Exhibit 99.2
a10x_logoxhorizontalxfullc.jpg
10x Genomics Announces Senior Leadership Changes
PLEASANTON, Calif., August 8, 2024 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today several changes to its executive team.
•Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company’s sales, support and marketing functions.
•Justin McAnear, Chief Financial Officer, will resign from the company, effective August 30, to join a private company.
•Adam Taich has been appointed Chief Financial Officer, effective August 12. Taich will be responsible for leading the company’s financial team and strategy.
“For the past two years, we’ve been intentionally evolving the company to continue to drive strong growth at scale, with across-the-board advances in how we innovate, operate and go-to-market,” said Serge Saxonov, CEO and Co-founder. “The changes we’re announcing today, along with the recent additions of Alan Mateo and Sarah Teichmann to our Board of Directors, are another step forward with these efforts. While we are sad to see Justin moving on, we are excited to attract such talented and seasoned leaders to help us execute our strategy, deliver the full promise of single cell and spatial biology and capture the incredible opportunity ahead.

“Justin has been a fantastic leader, a valued partner and a trusted friend. He helped to take 10x public, scaled the company and built a strong financial profile that has generated tremendous revenue growth and positive cash flow. As a result, we believe we are in a strong financial position and well set up for the future. On behalf of the Board and everyone at 10x, I want to thank Justin for his immeasurable contributions and wish him the best of luck in his new role.

“With Justin’s departure, I’m very excited to welcome Adam to 10x as our Chief Financial Officer. Adam is a seasoned executive and strategic finance leader who has held many leadership roles across functions in both large and small high growth companies. He brings a unique set of industry, strategic and operational perspectives to the role and to our senior team.

“Finally, throughout our extensive search process, Mennah distinguished herself and emerged as the best candidate to lead our commercial function in this next phase. She has done an exceptional job as our interim CCO, building a strong leadership team, setting a clear vision for our commercial strategy and rapidly implementing foundational processes to better enable the success of our customers and our company. I couldn’t be more excited to have Mennah at the helm as we work together to build a premier commercial organization that delivers superior execution and superior results.”

McAnear said, “It's been an honor to be part of the 10x team over the past six years. I'm extremely proud of how much we have accomplished and how much we have grown – from a single product company to a scaled organization with three leading platforms across single cell and spatial biology. I firmly believe 10x will continue to lead and has a very bright future ahead.”
Added Moustafa, “I couldn’t be more excited to be working alongside such a talented team as we continue to build a high-performance commercial organization, strengthen our commercial machinery and scale into the future. I see a huge opportunity to advance the field, and the entire commercial team is motivated and rallied to pursue widespread adoption of 10x technologies so we can advance our mission and accelerate the mastery of biology.”
Taich said, “I’ve always believed 10x is one of the most exciting companies in the industry, and I’m thrilled to work with this talented team to drive the next phase of growth and advance the company’s mission. I’ve spent my entire career in the life sciences tools sector in both operating and finance leadership roles. I’m energized by the incredible potential of single cell and spatial biology to transform human health.”

1
a10x_logoxhorizontalxfullc.jpg

About Mennah Moustafa
With more than two decades of commercial and business development experience, Moustafa is an accomplished leader with a proven track record of driving commercial success and building high-performance teams in the biotechnology and life sciences industry. Moustafa joined 10x Genomics in April 2022 as Senior Vice President of Commercial Operations and has served as the company’s interim Chief Commercial Officer since January 2024.

Prior to joining 10x Genomics, Moustafa served as Abcam’s Head of Commercial for the Americas before leading Business Development and later the Customer Experience Journey. She previously served as Vice President and Head of Business Development at Science Exchange and also held positions of increasing responsibility during her 10 years at Sigma-Aldrich, culminating as Director of Strategic Sales. Moustafa holds a bachelor’s degree in Neuroscience from the University of Minnesota.

About Adam Taich
Taich joins 10x Genomics from Standard BioTools Inc., where he was Chief Strategy Officer. He previously served as interim Chief Executive Officer of SomaLogic, Inc., a proteomics company. At SomaLogic, he previously held roles as Chief Business Officer and EVP of Life Sciences.

Earlier, Taich held a number of senior roles spanning finance, strategy and general management over a nearly 20-year career at Thermo Fisher Scientific, a global supplier of scientific instrumentation, reagents and software services. He spent the first 10 years of his time at Thermo Fisher in finance leadership roles and then transitioned into general management of scaled businesses. Prior to joining Thermo Fisher, he worked in investment banking. Taich holds a bachelor’s degree in Political Science and Russian from Miami University in Oxford, Ohio.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," “see,” "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," “deliver,” "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s expectations of size and growth of the opportunity ahead, the potential of single cell and spatial biology, financial prospects, commercial potential, organizations, operations, results and performance. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those suggested by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance, usage and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as
2
a10x_logoxhorizontalxfullc.jpg
required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.


Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
3
v3.24.2.u1
Cover
Aug. 06, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 06, 2024
Entity Registrant Name 10x Genomics, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39035
Entity Tax Identification Number 45-5614458
Entity Address, Address Line One 6230 Stoneridge Mall Road
Entity Address, City or Town Pleasanton
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94588
City Area Code 925
Local Phone Number 401-7300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, par value $0.00001 per share
Trading Symbol TXG
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001770787
10x Genomics (NASDAQ:TXG)
過去 株価チャート
から 11 2024 まで 12 2024 10x Genomicsのチャートをもっと見るにはこちらをクリック
10x Genomics (NASDAQ:TXG)
過去 株価チャート
から 12 2023 まで 12 2024 10x Genomicsのチャートをもっと見るにはこちらをクリック